88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections
PROUD UK PrEP study completes enrolment – first data give participants' background and risk factors
WHO recommends global use of newest hepatitis C drugs, urges price reductions
Hepatitis delta virus co-infection increases risk of poor liver-related outcomes for people living with HIV
Interferon-free BMS combo cures 90% of genotype 1 hepatitis C
Merck combination suppresses HCV in mono-infected and co-infected patients
Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b
Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients
